Metabolic Surgery for Treatment of Obesity

4 Min Read

Bariatric surgery is the leading non-pharmaceutical treatment for obesity. In fact, to date, it is the only effective, proven treatment for morbid obesity. Another phrase to describe surgery for weight loss is starting to come into use: metabolic surgery. This phrase better indicates the complexity of the systems which are involved in regulating and producing hunger, cravings, digestion and obesity.

Bariatric surgery is the leading non-pharmaceutical treatment for obesity. In fact, to date, it is the only effective, proven treatment for morbid obesity. Another phrase to describe surgery for weight loss is starting to come into use: metabolic surgery. This phrase better indicates the complexity of the systems which are involved in regulating and producing hunger, cravings, digestion and obesity.

Gastric bypass surgery is currently considered the gold standard in the US for surgical treatment of obesity. Studies have shown that patients tend to experience 50-80% excess weight loss (EWL) over a two year period following surgery. In addition, gastric bypass offers sustainable weight loss, and has a better record in this regard than does gastric banding.

Weight regain is not unknown, however, and has been reported to be as high as 25-30%, depending on the type of procedure and the patient’s dedication to changing. Patients must follow significant, permanent diet and lifestyle modifications following surgery, which is one reason why patients are usually required to undergo psychiatric testing and counseling prior to having the surgery. If weight is regained, then factors such as psychiatric challenges, the patient’s degree of adherence to the new diet, and general health must all be reviewed. Once these have been dealt with, then surgical revision may be considered.

Bariatric surgery falls into one of three categories, depending upon the type of procedure: restrictive, malabsorptive or a combination of these. ‘Restrictive’ refers to restricting the size of the stomach, so that the patient feels full on less food. This may be achieved using gastric stapling, gastric banding or by surgically removing a large part of the stomach. ‘Malabsorptive’ surgery involves making significant surgical changes to the digestive tract by bypassing most of the stomach and intestines, thereby shortening the absorptive surface area of the bowel. Because so much absorptive area is lost, the patient must take vitamins and minerals for the rest of his or her life.

Source: MedMarket Diligence, LLC; Report #S835.

(Note that high utilization shown above for Belgium is more representative of the country as a center of medical tourism than a source of obesity driving metabolic surgery in the country.)

In the US and European Union, bariatric surgeons generally perform the following major procedures:

  • Gastric bypass, including a variation known as vertical banded gastroplasty (VBG); the latter is both malabsorptive and restrictive.
  • Roux-en-Y (vertical division)
  • Sleeve gastrectomy independent of biliopancreatic diversion.
  • Biliopancreatic diversion with duodenal switch (both malabsorptive and restrictive)
  • Gastric banding (restrictive)

These may be performed using either open surgery or laparoscopically, but are usually done via laparoscope.

 

 

Share This Article
Follow:
I serve the interests of medical technology company decision-makers, venture-capitalists, and others with interests in medtech producing worldwide analyses of medical technology markets for my audience of mostly medical technology companies (but also rapidly growing audience of biotech, VC, and other healthcare decision-makers). I have a small staff and go to my industry insiders (or find new ones as needed) to produce detailed, reality-grounded analyses of current and potential markets and opportunities. I am principally interested in those core clinical applications served by medical devices, which are expanding to include biomaterials, drug-device hybrids and other non-device technologies either competing head-on with devices or being integrated with devices in product development. The effort and pain of making every analysis global in scope is rewarded by my audience's loyalty, since in the vast majority of cases they too have global scope in their businesses. Specialties: Business analysis through syndicated reports, and select custom engagements, on medical technology applications and markets in general/abdominal/thoracic surgery, interventional cardiology, cardiothoracic surgery, patient monitoring/management, wound management, cell therapy, tissue engineering, gene therapy, nanotechnology, and others.
Exit mobile version